Sorrento, Yuhan create a JV for checkpoint drugs

San Diego-based Sorrento Therapeutics ($SRNE) is forming a joint venture with South Korea's Yuhan to develop immune checkpoint antibodies for cancer. Yuhan is seeing ImmuneOncia Therapeutics with a $10 million payment. Release

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.